{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:43:52Z","timestamp":1790700232746,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Theoretical Biology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jtbi.2017.08.023","type":"journal-article","created":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T06:45:28Z","timestamp":1504334728000},"page":"94-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["A causal Bayesian network model of disease progression mechanisms in chronic myeloid leukemia"],"prefix":"10.1016","volume":"433","author":[{"given":"Daniel","family":"Koch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Eisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gebharter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtbi.2017.08.023_bib0001","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0002","doi-asserted-by":"crossref","first-page":"8912","DOI":"10.1158\/0008-5472.CAN-05-0076","article-title":"Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia","volume":"65","author":"Barnes","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0003","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1182\/blood.V91.9.3414","article-title":"Inhibition of BCR-ABL expression with antisense oligonucleotides restores \u00df1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoetic progenitors","volume":"91","author":"Bhatia","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-013-0196-8","article-title":"Maintaining Low BCR-ABL signaling output to restrict CML progression and enable persistence","volume":"9","author":"Burchert","year":"2014","journal-title":"Curr. Hematol Malig. Rep."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0005","series-title":"Model Selection and Multimodal Inference. A Practical Information-Theoretic Approach","author":"Burnham","year":"2002"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0006","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0007","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0008","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s11229-013-0360-7","article-title":"Modeling mechanisms with causal cycles","volume":"191","author":"Clarke","year":"2014","journal-title":"Synthese"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0009","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.hoc.2004.03.012","article-title":"Clonal evolution in chronic myelogenous leukemia","volume":"18","author":"Cortes","year":"2004","journal-title":"Hematol Oncol Clin. North Am."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.2517-6161.1977.tb01600.x","article-title":"Maximum likelihood from incomplete data via the EM algorithm","volume":"39","author":"Dempster","year":"1977","journal-title":"J. R. Stat. Soc. Ser. B."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0011","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia","volume":"355","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0012","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the bcr-abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"355","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0013","first-page":"994","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"344","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000503","article-title":"Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib","volume":"5","author":"Foo","year":"2009","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0015","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood.V86.6.2371.bloodjournal8662371","article-title":"Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression","volume":"86","author":"Gaiger","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0016","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0933-3657(02)00027-1","article-title":"NasoNet, modeling the spread of nasopharyngeal cancer with networks of probabilistic events in discrete time","volume":"25","author":"Gal\u00e1n","year":"2005","journal-title":"Artif. Intell. Med."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0017","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1086\/687876","article-title":"A modeling approach for mechanisms featuring causal cycles","volume":"83","author":"Gebharter","year":"2016","journal-title":"Philos Sci."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0018","first-page":"1153","article-title":"Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein","volume":"11","author":"Gotoh","year":"1995","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0019","first-page":"3048","article-title":"Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients","volume":"51","author":"Guo","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0020","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0021","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/344251a0","article-title":"Acute leukaemia in bcr\/abl transgenic mice","volume":"344","author":"Heisterkamp","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0023","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1269\/jrr.19.262","article-title":"Incidence of leukemia in atomic bomb survivors belonging to a fixed cohort in Hiroshima and Nagasaki","volume":"19","author":"Ichimaru","year":"1978","journal-title":"J. Radiat. Res."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0024","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3109\/10428194.2013.845883","article-title":"Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia","volume":"55","author":"Jabbour","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0025","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.leu.2403626","article-title":"BCR\/ABL-mediated downregulation of genes implicated in cell adhesion and motility leads to impaired migration toward CCR7 ligands CCL19 and CCL21 in primary BCR\/ABL- positive cells","volume":"19","author":"Jongen-Lavrencic","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0026","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1002\/1097-0142(20011115)92:10<2501::AID-CNCR1600>3.0.CO;2-N","article-title":"Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase","volume":"92","author":"Kantarjian","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0028","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0029","series-title":"Bayesian Artificial Intelligence","author":"Korb","year":"2011"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0058","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/nature03669","article-title":"Dynamics of chronic myeloid leukaemia","volume":"435","author":"Michor","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0030","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1634\/stemcells.2006-0638","article-title":"Chronic myeloid leukemia blast crisis arises from progenitors","volume":"25","author":"Michor","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0031","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1200\/JCO.2007.15.2421","article-title":"Mathematical models of cancer stem cells","volume":"26","author":"Michor","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0032","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1182\/blood-2006-06-032490","article-title":"Role of BCR\/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoetic cells","volume":"109","author":"Modi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0033","series-title":"Probabilistic Reasoning in Expert Systems","author":"Neapolitan","year":"1990"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0034","doi-asserted-by":"crossref","first-page":"e129","DOI":"10.1371\/journal.pcbi.0030129","article-title":"A primer on learning in Bayesian networks for computational biology","volume":"3","author":"Needham","year":"2007","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0035","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0036","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","article-title":"Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0037","series-title":"Causality","author":"Pearl","year":"2000"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0038","series-title":"Probabilistic reasoning in intelligent systems: Networks of plausible inference","author":"Pearl","year":"1988"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0057","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1182\/blood-2003-09-3033","article-title":"Lack of adhesion molecules P-selectin and intercellular adhesion molecule-1 accelerate the development of BCR\/ABL-induced chronic myeloid leukemia-like myeloproliferative disease in mice","volume":"104","author":"Pelletier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0059","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1200\/JCO.2004.03.050","article-title":"Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients","volume":"22","author":"Peng","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0039","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0040","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1\u2013positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0041","series-title":"Molecular Hematology","first-page":"76","article-title":"Chronic myelogenous leukemia","author":"Quint\u00e1s-Cardama","year":"2010"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0042","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0043","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/asheducation-2007.1.384","article-title":"The biology of CML blast crisis","volume":"2007","author":"Radich","year":"2007","journal-title":"Hematology Am. Soc. Hematol. Educ. Program."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0044","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0045","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/nm1487","article-title":"Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional insights and clinical implications","volume":"12","author":"Roeder","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0046","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/156800911793743619","article-title":"Molecular pathogenesis of philadelphia-positive chronic myeloid leukemia \u2013 is it all BCR- ABL?","volume":"11","author":"Rumpold","year":"2011","journal-title":"Curr. Cancer Drug Tar."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0047","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1126\/science.1105809","article-title":"Causal protein-signaling networks derived from multiparameter single-cell data","volume":"308","author":"Sachs","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0048","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/0008-5472.CAN-10-4600","article-title":"A multicellular basis for the origination of blast crisis in chronic myeloid leukemia","volume":"71","author":"Sachs","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0049","doi-asserted-by":"crossref","first-page":"8605","DOI":"10.1038\/sj.onc.1206088","article-title":"Mechanisms underlying abnormal trafficking and expansion of malignant progenitors in CML: BCR\/ABL-induced defects in integrin function in CML","volume":"21","author":"Salesse","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0050","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1074\/jbc.270.10.5039","article-title":"Molecular cloning of human paxillin, a focal adhesion protein phosphorylated by P210BCR\/ABL","volume":"270","author":"Salgia","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0051","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0052","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.leu.2402577","article-title":"Chronic myelogenous leukemia: mechanisms underlying disease progression","volume":"16","author":"Shet","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0053","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.beha.2009.07.006","article-title":"The blast phase of chronic myeloid leukaemia","volume":"22","author":"Silver","year":"2009","journal-title":"Best Prac. Res. Clin. Hematol."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0054","series-title":"Causation, Prediction and Search","author":"Spirtes","year":"1993"},{"key":"10.1016\/j.jtbi.2017.08.023_bib0055","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0022-2143(97)90192-X","article-title":"Pathophysiology of CML: do defects in integrin function contribute to the premature circulation and massive expansion of the BCR\/ABL positive clone?","volume":"129","author":"Verfaillie","year":"1997","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.jtbi.2017.08.023_bib0056","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1172\/JCI115985","article-title":"Mechanisms underlying abnormal trafficking. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV","volume":"90","author":"Verfaillie","year":"1992","journal-title":"J. Clin. Invest."}],"container-title":["Journal of Theoretical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022519317303983?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022519317303983?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T17:33:48Z","timestamp":1719423228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022519317303983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":57,"alternative-id":["S0022519317303983"],"URL":"https:\/\/doi.org\/10.1016\/j.jtbi.2017.08.023","relation":{},"ISSN":["0022-5193"],"issn-type":[{"value":"0022-5193","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A causal Bayesian network model of disease progression mechanisms in chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Theoretical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtbi.2017.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}